Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | DGAT1 | O75907 | 5/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 10/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | FYN | P06241 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.42 |
| ▸ | CCR4 | P51679 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3111183 | 1.00 | MAPT (1.00) | MAPTKDM4ELMNAALDH1A1GAA | |
| SCHEMBL2543291 | 1.00 | MAPT (1.00) | MAPTKDM4ELMNAALDH1A1GAA | |
| SCHEMBL9775989 | 0.89 | MAPT (0.80) | MAPTKDM4ELMNAALDH1A1GAA | |
| SCHEMBL14765200 | 0.89 | MAPT (0.80) | MAPTKDM4ELMNAALDH1A1GAA | |
| SCHEMBL23355483 | 0.89 | MAPT (0.80) | MAPTKDM4ELMNAALDH1A1GAA | |
| SCHEMBL12240584 | 0.89 | MAPT (0.80) | MAPTKDM4ELMNAALDH1A1GAA | |
| SCHEMBL19730460 | 0.89 | MAPT (0.80) | MAPTKDM4ELMNAALDH1A1GAA | |
| SCHEMBL23678506 | 0.89 | MAPT (0.80) | MAPTKDM4ELMNAALDH1A1GAA | |
| SCHEMBL16975619 | 0.89 | MAPT (0.80) | MAPTKDM4ELMNAALDH1A1GAA | |
| SCHEMBL16249928 | 0.88 | MAPT (0.78) | MAPTKDM4ELMNAALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104774195-A | Optically pure itraconazole key intermediate, synthetic method thereof, and method for synthesizing optically pure itraconazole from the intermediate | YANGZHOU AIDEA BIOTECH CO LTD | 2015-07-15 | — | — | CN | claimed |
| US-20130102614-A1 | CHIRALLY PURE ISOMERS OF ITRACONAZOLE FOR USE AS ANGIOGENESIS INHIBITORS | JOHNS HOPKINS UNIVERSITY | 2013-04-25 | — | — | US | claimed |
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | claimed |
| EP-3250036-B1 | SMALL MOLECULE INHIBITORS OF FIBROSIS | SCRIPPS RESEARCH INST (US) | 2021-05-12 | — | — | EP | disclosed |
| US-20200317649-A1 | AZOLE ANALOGUES AND METHODS OF USE THEREOF | UNIVERSITY OF CONNECTICUT | 2020-10-08 | — | — | US | disclosed |
| US-10336735-B2 | Small molecule inhibitors of fibrosis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2019-07-02 | — | — | US | disclosed |
| CN-104774195-B | A kind of optical voidness itraconazole key intermediate and synthetic method and the method by the pure Itraconazole of intermediate synthesizing optical | 江苏艾迪药业有限公司 | 2018-09-07 | — | — | CN | disclosed |
| US-20170362211-A1 | SMALL MOLECULE INHIBITORS OF FIBROSIS | THE SCRIPPS RESEARCH INSTITUTE | 2017-12-21 | — | — | US | disclosed |
| US-20170362211-A1 | SMALL MOLECULE INHIBITORS OF FIBROSIS | THE SCRIPPS RESEARCH INSTITUTE | 2017-12-21 | — | — | US | disclosed |
| WO-2016094570-A1 | SMALL MOLECULE INHIBITORS OF FIBROSIS | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2016-06-16 | — | — | WO | disclosed |
| US-9095589-B2 | Chirally pure isomers of itraconazole for use as angiogenesis inhibitors | JOHNS HOPKINS UNIVERSITY (US) | 2015-08-04 | — | — | US | disclosed |
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | disclosed |
| EP-2183225-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| EP-1673368-B1 | AZOLE DERIVATIVE USEFUL AS ANTIFUNGAL AGENTS WITH REDUCED INTERACTION WITH METABOLIC CYTOCHROMES | ITALFARMACO SPA (IT) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009012421-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-01-22 | — | — | WO | disclosed |
| US-7427620-B2 | Azole derivative useful as antifungal agents with reduced interaction with metabolic cytochromes | ITALFARMACO SPA (IT) | 2008-09-23 | — | — | US | disclosed |
| US-20070129376-A1 | Azole derivative useful as antifungal agents with reduced interaction with metabolic cytochromes | ITALFARMACO SPA. (IT) | 2007-06-07 | — | — | US | disclosed |
| EP-1673368-A1 | AZOLE DERIVATIVE USEFUL AS ANTIFUNGAL AGENTS WITH REDUCED INTERACTION WITH METABOLIC CYTOCHROMES | ITALFARMACO S.p.A. (IT) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005040156-A1 | AZOLE DERIVATIVE USEFUL AS ANTIFUNGAL AGENTS WITH REDUCED INTERACTION WITH METABOLIC CYTOCHROMES | ITALFARMACO S.P.A. (IT) | 2005-05-06 | — | — | WO | disclosed |
| US-6346518-B1 | ADMINISTERING AS A COMPLEX WITH CYCLODEXTRIN TO TREAT FUNGAL INFECTIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | PRKCH, PKD2, PRKCQ | MAPT 3398/4885KDM4E 1426/4885LMNA 1792/4885 |
| US-20200317649-A1 | AZOLE ANALOGUES AND METHODS OF USE THEREOF | SHH, SMO, GLI1 | MAPT 3664/4885KDM4E 3053/4885LMNA 3327/4885 |
| US-10336735-B2 | Small molecule inhibitors of fibrosis | MMP1, COL2A1, MMP8 | MAPT 4142/4885KDM4E 2499/4885LMNA 2026/4885 |
| US-20170362211-A1 | SMALL MOLECULE INHIBITORS OF FIBROSIS | MMP1, COL2A1, MMP8 | MAPT 4142/4885KDM4E 2499/4885LMNA 2026/4885 |
| US-20070129376-A1 | Azole derivative useful as antifungal agents with reduced interaction with metabolic cytochromes | CYP51A1, CYP3A5, CYP11B1 | MAPT 3506/4885KDM4E 3984/4885LMNA 4244/4885 |
| US-20130102614-A1 | CHIRALLY PURE ISOMERS OF ITRACONAZOLE FOR USE AS ANGIOGENESIS INHIBITORS | TEK, KDR, FLT1 | MAPT 4131/4885KDM4E 4383/4885LMNA 4600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.